search
Back to results

Viagra in the Treatment of Primary Dysmenorrhea

Primary Purpose

Dysmenorrhea

Status
Completed
Phase
Phase 1
Locations
Croatia
Study Type
Interventional
Intervention
Sildenafil Citrate
Placebo
Sponsored by
Milton S. Hershey Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dysmenorrhea focused on measuring Sildenafil

Eligibility Criteria

18 Years - 35 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Primary dysmenorrhea at current visit, with a visual analogue scale (VAS) score of >35; pain defined as moderate or severe on a categorical of none, mild, moderate, severe. Exclusion Criteria: Secondary dysmenorrhea Any current medication Serious medical condition

Sites / Locations

  • Nova Gradiska General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Sildenafil Citrate

Placebo

Arm Description

A single vaginal dose of Viagra 100 mg.

A single vaginal dose of placebo.

Outcomes

Primary Outcome Measures

The Primary Outcome Was Total Pain Relief Over 4 Hours (TOPAR4), Comparing a Single Dose of Sildenafil 100 mg to a Single Dose of Placebo.
The Total Pain Relief (TOPAR) Scale rates the level of pain relief on a scale of 0=None, 1=Mild, 2=Moderate, 3=Excellent, 4=Complete. The TOPAR scale was completed each hour after administration of study drug for a total of 4 hours. The 4 hourly scores were summed for a final TOPAR4 score that ranged between 0 and 16, with higher values indicating greater pain relief over time. Missing TOPAR scores after the first hour were imputed using the last-observation-carried-forward approach.

Secondary Outcome Measures

Improvement in Pain Severity Determined by Visual Analog Scale (VAS).
The Visual Analog Scale (VAS) assesses pain intensity. The scale is 100 mm long; the extremes of the scale are to the left, "no pain" and to the right, "worst pain I have ever felt." The VAS score is determined by measuring the distance (in mm) from the left side of the scale to the point that the patient marked. The score ranges from 0 to 100, with higher values indicating greater pain.

Full Information

First Posted
July 20, 2005
Last Updated
November 18, 2015
Sponsor
Milton S. Hershey Medical Center
Collaborators
National Institutes of Health (NIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00123162
Brief Title
Viagra in the Treatment of Primary Dysmenorrhea
Official Title
Sildenafil Citrate in the Treatment of Primary Dysmenorrhea
Study Type
Interventional

2. Study Status

Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
May 2007 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Milton S. Hershey Medical Center
Collaborators
National Institutes of Health (NIH)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary hypothesis is that a 100mg single dose of sildenafil citrate (Viagra) will have a higher improvement rate when compared to placebo in the treatment of moderate to severe primary dysmenorrhea.
Detailed Description
It is well established that excess prostaglandin production in primary dysmenorrhea leads to ischemia of the uterine muscle, which consequently causes pelvic pain. A large number of drugs have been studied for pain relief in dysmenorrhea patients, with non-steroid anti-inflammatory drugs (NSAIDS) being the most effective with the overall success rate of more than 75%. Sildenafil citrate (Viagra) is an inhibitor that augments the vasodilatory effects of nitric oxide by preventing the degradation of Cyclic guanosine monophosphate (cGMP) in the uterine muscle. Sildenafil is commonly used in the treatment of male erectile dysfunction, pulmonary hypertension in children and adults, and in vitro fertilization. To date it has not been used in the treatment of primary dysmenorrhea.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dysmenorrhea
Keywords
Sildenafil

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sildenafil Citrate
Arm Type
Experimental
Arm Description
A single vaginal dose of Viagra 100 mg.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
A single vaginal dose of placebo.
Intervention Type
Drug
Intervention Name(s)
Sildenafil Citrate
Other Intervention Name(s)
Viagra
Intervention Description
A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Sugar Pill
Intervention Description
A single vaginal dose of placebo and monitored for 4 hours.
Primary Outcome Measure Information:
Title
The Primary Outcome Was Total Pain Relief Over 4 Hours (TOPAR4), Comparing a Single Dose of Sildenafil 100 mg to a Single Dose of Placebo.
Description
The Total Pain Relief (TOPAR) Scale rates the level of pain relief on a scale of 0=None, 1=Mild, 2=Moderate, 3=Excellent, 4=Complete. The TOPAR scale was completed each hour after administration of study drug for a total of 4 hours. The 4 hourly scores were summed for a final TOPAR4 score that ranged between 0 and 16, with higher values indicating greater pain relief over time. Missing TOPAR scores after the first hour were imputed using the last-observation-carried-forward approach.
Time Frame
Hours 1, 2, 3 and 4.
Secondary Outcome Measure Information:
Title
Improvement in Pain Severity Determined by Visual Analog Scale (VAS).
Description
The Visual Analog Scale (VAS) assesses pain intensity. The scale is 100 mm long; the extremes of the scale are to the left, "no pain" and to the right, "worst pain I have ever felt." The VAS score is determined by measuring the distance (in mm) from the left side of the scale to the point that the patient marked. The score ranges from 0 to 100, with higher values indicating greater pain.
Time Frame
Each hour of the study (0, 1, 2, 3, 4).

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Primary dysmenorrhea at current visit, with a visual analogue scale (VAS) score of >35; pain defined as moderate or severe on a categorical of none, mild, moderate, severe. Exclusion Criteria: Secondary dysmenorrhea Any current medication Serious medical condition
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Legro, M.D.
Organizational Affiliation
Penn State University College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nova Gradiska General Hospital
City
Strossmayerova 17
State/Province
Zagreb
Country
Croatia

12. IPD Sharing Statement

Citations:
PubMed Identifier
23925396
Citation
Dmitrovic R, Kunselman AR, Legro RS. Sildenafil citrate in the treatment of pain in primary dysmenorrhea: a randomized controlled trial. Hum Reprod. 2013 Nov;28(11):2958-65. doi: 10.1093/humrep/det324. Epub 2013 Aug 6.
Results Reference
derived

Learn more about this trial

Viagra in the Treatment of Primary Dysmenorrhea

We'll reach out to this number within 24 hrs